open access

Vol 10, Supp. G (2014)
suplement
Published online: 2015-03-20
Get Citation

Treatment with erlotinib in 58-year old woman with liver damage and depression as the first sign of metastases to the central nervous system

Marcin Gołecki

open access

Vol 10, Supp. G (2014)
suplement
Published online: 2015-03-20

Abstract

Molecularly targeted therapy with EGFR tyrosine kinase inhibitors has become an important enhancement of systemic non-small cell lung cancer therapy in recent years. Current standards strongly recommend this treatment if EGFR activating mutations are present in lung cancer cells. In this article the case of a patient with non-small cell lung cancer and positive EGFR activating mutations is described, who was treated with erlotinib despite liver damage, achieved long-lasting regression in the lungs, the reduction of the transaminases activity in the course of treatment and finally depression as a first sign of the central nervous system progression.

Abstract

Molecularly targeted therapy with EGFR tyrosine kinase inhibitors has become an important enhancement of systemic non-small cell lung cancer therapy in recent years. Current standards strongly recommend this treatment if EGFR activating mutations are present in lung cancer cells. In this article the case of a patient with non-small cell lung cancer and positive EGFR activating mutations is described, who was treated with erlotinib despite liver damage, achieved long-lasting regression in the lungs, the reduction of the transaminases activity in the course of treatment and finally depression as a first sign of the central nervous system progression.

Get Citation

Keywords

erlotinib, liver damage, depression, MRI, CNS metastases

About this article
Title

Treatment with erlotinib in 58-year old woman with liver damage and depression as the first sign of metastases to the central nervous system

Journal

Oncology in Clinical Practice

Issue

Vol 10, Supp. G (2014)

Pages

1-5

Published online

2015-03-20

Keywords

erlotinib
liver damage
depression
MRI
CNS metastases

Authors

Marcin Gołecki

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl